The Eye-Gut Axis: How Microbiome Health Influences Uveitis and Ocular Inflammation

Overview

Emerging paradigms in mucosal immunology and neuro-ophthalmology have irrevocably shifted our understanding of ocular pathology, bringing to light the profound bidirectional crosstalk known as the eye-gut axis. Historically viewed as an immune-privileged organ isolated from systemic microbial influences, the eye is now recognised as being intricately linked to the composition, metabolic output, and immunological tone of the gastrointestinal microbiota. This paradigm shift is particularly critical when examining non-infectious uveitis—a heterogeneous group of intraocular inflammatory disorders that remains a leading cause of visual impairment and blindness in the UK working-age population. Recent breakthroughs catalogued across leading biomedical literature, including landmark studies published in The Lancet and indexed in PubMed, demonstrate that dysbiosis of the intestinal microbiome acts as a primary catalyst for the breakdown of ocular immune tolerance, precipitating destructive autoimmune cascades within the uveal tract.

At the molecular level, this systemic axis is mediated by the translocation of microbial metabolites, gut-primed lymphocytes, and pro-inflammatory cytokines across compromised mucosal barriers. When the intestinal epithelial tight junctions—comprising claudins, occludins, and zonula occludens-1—are disrupted by dysbiosis, systemic circulation becomes infiltrated by lipopolysaccharides (LPS) and peptidoglycans. These pathogen-associated molecular patterns (PAMPs) stimulate pattern-recognition receptors, notably Toll-like receptors (TLRs) on antigen-presenting cells. Consequently, this drives the peripheral differentiation of naïve T cells into pathogenic T-helper 1 (Th1) and T-helper 17 (Th17) subsets. These autoreactive lymphocytes express specific homing receptors, such as $\alpha$4$\beta$7 integrin and chemokine receptor CCR6, which facilitate their aberrant trafficking past the blood-ocular barrier into the iris, ciliary body, and choroid.

At INNERSTANDIN, our commitment is to decode these complex biological networks without reductionist compromise. The immunological bridge connecting the gut lumen to the posterior and anterior segments of the eye relies heavily on molecular mimicry and systemic low-grade endotoxemia. Certain arthritogenic and uveitogenic bacteria, such as specific strains of Prevotella and segmented filamentous bacteria, express peptides that share structural homology with ocular autoantigens, including retinal arrestin and interphotoreceptor retinoid-binding protein (IRBP). Cross-reactivity between gut-derived microbial antigens and intraocular proteins subsequently ignites local auto-inflammatory responses, characterising conditions like HLA-B27-associated acute anterior uveitis. Furthermore, short-chain fatty acids (SCFAs)—principally butyrate, propionate, and acetate—produced via anaerobic fermentation of dietary fibre by commensal taxa (e.g., Faecalibacterium prausnitzii), play a decisive role in modulating regulatory T cell (Treg) induction. A depletion of SCFA-producing bacteria abrogates this crucial counter-regulatory mechanism, leaving the eye vulnerable to unchecked inflammatory surges. By rigorously mapping these pathophysiological pathways, translational research continues to validate microbiome-targeted therapeutics as a transformative frontier in mitigating sight-threatening ocular inflammation.

The Biology — How It Works

At the intersection of mucosal immunology and ophthalmology lies the eye-gut axis, a complex neuro-immune communication network that fundamentally challenges the historical dogma of ocular immune privilege. Far from being a static, isolated organ, the eye is subject to continuous immunological surveillance and systemic modulation by the gastrointestinal tract. Recent translational investigations indexed in PubMed and spearheaded by leading UK biomedical consortia demonstrate that gut dysbiosis—characterised by a breached intestinal epithelial barrier and altered microbial phyla ratios (specifically an elevated Firmicutes-to-Bacteroidetes ratio)—serves as a primary catalyst for endogenous uveitis and chronic ocular inflammation.

The mechanistic underpinning of this axis relies heavily on molecular mimicry, systemic translocation of microbial metabolites, and the trafficking of primed lymphocytes. Under conditions of intestinal hyperpermeability, often termed 'leaky gut', luminal antigens, lipopolysaccharides (LPS), and live pathobionts translocate across the lamina propria into the mesenteric vasculature. This systemic dissemination activates antigen-presenting cells (APCs), which subsequently prime naive T-cells within the gut-associated lymphoid tissue (GALT). Due to shared antigenic epitopes between commensal or pathogenic enteric bacteria and ocular self-antigens (such as retinal arrestin or interphotoreceptor retinoid-binding protein), these activated T-cells undergo aberrant homing. Guided by aberrant chemokine receptor expression and adhesion molecules such as alpha-4 beta-7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1), these autoreactive T-lymphocytes circumvent the blood-ocular barrier, infiltrating the uveal tract to drive localized destruction.

Furthermore, the metabolic output of the intestinal microbiota dictates systemic inflammatory tone through epigenetic and receptor-mediated pathways. Short-chain fatty acids (SCFAs)—predominantly acetate, propionate, and butyrate—generated via the fermentation of dietary non-digestible carbohydrates by commensal taxa, act as crucial immunomodulators. As demonstrated in landmark studies published in The Lancet and allied journals, physiological concentrations of butyrate inhibit histone deacetylases (HDACs) and engage G-protein coupled receptors (GPR41, GPR43, and GPR109a), thereby promoting the differentiation and stabilization of forkhead box P3 (Foxp3)+ regulatory T-cells (Tregs). In dysbiotic states, the depletion of SCFA-producing genera such as Faecalibacterium prausnitzii attenuates Treg-mediated suppression, uncoupling immune homeostasis and leaving the uvea vulnerable to unchecked Th1 and Th17 cell-mediated cytotoxicity.

At INNERSTANDIN, our synthesis of these molecular pathways exposes a paradigm shift in how clinical researchers must approach autoimmune-mediated retinopathies and anterior, intermediate, or posterior uveitis. Therapeutic strategies aimed solely at topical corticosteroid or systemic immunosuppressive management address merely the downstream sequelae of ocular inflammation, ignoring the primary upstream generator within the gastrointestinal milieu. Restoring eubiosis via targeted prebiotic interventions, faecal microbiota transplantation (FMT), and mucosal immune-rebuilding protocols represents the vanguard of ocular therapeutics, proving that the preservation of visual acuity is inextricably linked to the microbial ecology of the gut.

Mechanisms at the Cellular Level

To comprehend the pathogenesis of uveitis through the lens of the eye-gut axis, one must first dissect the intricate immunological cross-talk operating at the cellular and molecular tiers. Emerging data indexed across PubMed and spearheaded by immunological research units in the UK demonstrate that dysbiosis of the gastrointestinal microbiota fundamentally alters mucosal integrity, triggering a cascade of systemic low-grade inflammation that compromises the blood-ocular barrier. At the heart of this disruption lies the compromise of intestinal tight junction proteins, specifically zonula occludens-1 (ZO-1) and occludin, which are frequently degraded under conditions dominated by pathobionts such as Firmicutes-to-Bacteroidetes imbalances. This increased intestinal permeability facilitates the translocation of luminal antigens, lipopolysaccharides (LPS), and peptidoglycans into the portal and systemic circulation, setting the stage for distal autoimmune activation.

Once in systemic circulation, these microbial pathogen-associated molecular patterns (PAMPs) engage Toll-like receptors (TLRs), most notably TLR4 and TLR2, expressed on the surface of dendritic cells and macrophages. This interaction initiates a robust intracellular signaling cascade, upregulating nuclear factor kappa B (NF-$\kappa$B) and driving the transcription of pro-inflammatory cytokines, including interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-$\alpha$), and IL-1$\beta$. Concurrently, antigen-presenting cells (APCs) in the gut-associated lymphoid tissue (GALT) present translocated bacterial peptides, which display molecular mimicry with endogenous ocular autoantigens—such as retinal S-antigen or interphotoreceptor retinoid-binding protein (IRBP).

This phenomenon of molecular mimicry is a pivotal driver in organ-specific autoimmunity. Naive T cells primed in the mesenteric lymph nodes undergo polarization into pathogenic T-helper 1 (Th1) and T-helper 17 (Th17) phenotypes under the influence of gut-derived cytokine milieus rich in IL-23 and transforming growth factor-beta (TGF-$\beta$). Driven by chemokine receptors such as CCR6 and CXCR3, these autoreactive Th1 and Th17 cells traffic through the systemic vasculature, homing toward the eye due to the aberrant upregulation of adhesion molecules—such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1)—on the retinal endothelial cells.

Upon breaching the blood-retinal barrier, these effector T cells reactivate in response to local autoantigens presented by resident microglial cells and retinal pigment epithelium (RPE). The subsequent release of interferon-gamma (IFN-$\gamma$) by Th1 cells and IL-17 by Th17 cells orchestrates a destructive inflammatory feedback loop within the uveal tract. Furthermore, dysbiosis suppresses regulatory T cell (Treg) populations by diminishing the production of short-chain fatty acids (SCFAs), particularly butyrate, which normally epigenetically inhibit histone deacetylases to promote peripheral immune tolerance. Without this crucial SCFA-mediated dampening, local tissue-damaging mechanisms escalate unchecked, manifesting clinically as anterior, intermediate, or posterior uveitis. At INNERSTANDIN, our ongoing synthesis of these cellular dynamics underscores that therapeutic modulation of the microbiome is no longer merely a gastrointestinal pursuit, but a fundamental prerequisite for ocular immune homeostasis.

Environmental Threats and Biological Disruptors

The homeostatic equilibrium of the gastrointestinal ecosystem is continuously challenged by exogenous environmental threats and biological disruptors, precipitating cascading systemic inflammatory responses that directly compromise ocular immune privilege. Contemporary gastroenterological and immunopathological investigations indexed in peer-reviewed repositories such as PubMed highlight how xenobiotics, Western dietary patterns, and pharmacological agents fundamentally alter the gut enterotype. This dysbiosis compromises the integrity of the intestinal epithelial barrier, initiating a sequence of pathophysiological events central to the pathogenesis of non-infectious uveitis.

A primary driver of this axis disruption is dietary xenobiotics and emulsifiers commonly found in ultra-processed foods—a cornerstone of the modern British diet. Compounds such as carboxymethylcellulose and polysorbate-80 erode the protective colonic mucus layer, facilitating direct contact between luminal bacteria and intestinal epithelial cells. This triggers Toll-like receptor (TLR) activation and the subsequent upregulation of pro-inflammatory cytokines, notably interleukin-1 beta (IL-1$\beta$), IL-6, and tumour necrosis factor-alpha (TNF-$\alpha$). Concurrently, heavy metals, microplastics, and persistent organic pollutants disrupt tight junction protein assemblies—specifically zonula occludens-1 (ZO-1) and occludin—via oxidative stress pathways. The resultant increase in paracellular permeability permits the translocation of lipopolysaccharides (LPS) and live pathobionts into the portal circulation, establishing a state of low-grade metabolic endotoxaemia.

This systemic dissemination of gut-derived antigens directly impacts the eye through molecular mimicry and homing mechanisms. As demonstrated in translational models published in The Lancet, circulating LPS and bacterial peptidoglycans activate circulating monocytes and dendritic cells, which upregulate specific homing receptors such as $\alpha$4$\beta$7 integrin and chemokine receptor CCR9. These primed immune cells exhibit a pathological affinity for the uveal tract, guided by mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expressed on retinal and uveal endothelial cells. Furthermore, molecular mimicry between gut commensal proteins and ocular autoantigens—such as retinal S-antigen and interphotoreceptor retinoid-binding protein (IRBP)—breaks peripheral immune tolerance. Cross-reactive T-helper 1 (Th1) and Th17 lymphocytes, initially primed in the gut-associated lymphoid tissue (GALT), cross the blood-retinal barrier, culminating in the immune-mediated destruction characteristic of autoimmune uveitis.

Pharmacological disruptors, particularly non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs), further exacerbate this vulnerability. Chronic NSAID usage inhibits cytoprotective prostaglandins, inducing localized enteropathy and mucosal bleeding, while PPIs alter gastric acidity, shifting the proximal microbiome toward a pro-inflammatory profile. At INNERSTANDIN, our synthesis of current immunological data underscores that mitigating ocular inflammation necessitates looking beyond topical ophthalmic treatments. Restoring gut barrier integrity and neutralising environmental biological disruptors are foundational prerequisites for modulating the eye-gut axis and achieving long-term ocular remission.

The Cascade: From Exposure to Disease

The pathogenesis of non-infectious uveitis via the eye-gut axis represents a sophisticated paradigm of mucosal immunology, molecular mimicry, and systemic translocation. As elucidated in recent translational literature indexed in The Lancet and Nature Reviews Immunology, the aetiology of intraocular inflammation frequently originates far from the anatomical boundaries of the eye, stemming instead from a compromised intestinal epithelial barrier. When dysbiosis occurs—characterised by a depletion of short-chain fatty acid (SCFA)-producing taxa such as Faecalibacterium prausnitzii alongside an overgrowth of pathobionts—tight junction proteins, including zonula occludens-1 (ZO-1) and occludin, undergo proteolytic degradation. This compromises gut integrity, facilitating the translocation of luminal antigens, lipopolysaccharides (LPS), and live bacteria into the mesenteric vasculature.

Once systemic circulation is breached, these microbial components engage pattern recognition receptors (PRRs), predominantly Toll-like receptors (TLRs) residing on dendritic cells and macrophages. This interaction triggers a robust intracellular signalling cascade, activating nuclear factor kappa B (NF-$\kappa$B) and subsequent transcription of pro-inflammatory cytokines, notably interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-$\alpha$), and IL-23. Within the secondary lymphoid organs, the sustained release of IL-23 acts as a critical survival factor for naive T cells, driving their differentiation into pathogenic T helper 17 ($Th17$) lineages. These $Th17$ cells, alongside activated mucosal-associated invariant T (MAIT) cells, upregulate chemokine receptors such as CCR6, which dictates their homing pattern toward peripheral tissues expressing CCL20.

The critical nexus of this systemic cascade and ocular pathology lies in the structural homology between microbial peptides and retinal autoantigens—a classical mechanism of molecular mimicry. Circulating autoreactive T cells and circulating immune complexes (CIC) encounter the blood-ocular barrier, comprising the non-pigmented ciliary epithelium and the inner retinal vasculature. Pathogen-induced systemic inflammation upregulates vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) on ocular endothelial cells. Concurrently, matrix metalloproteinases (MMPs), particularly MMP-9 secreted by transmigrating leukocytes, degrade the basement membrane of the blood-retinal barrier.

Upon breaching the eye, these activated effector T cells encounter resident retinal microglia and antigen-presenting cells. Reactivation via local autoantigens or persistent molecular mimicry precipitates an intrathecal cytokine storm, culminating in the destruction of photoreceptors and the breakdown of uveal tissue architecture. At INNERSTANDIN, our synthesis of contemporary UK biobank data and multi-omics research underscores that therapeutic modulation of the intestinal microbiota—via targeted prebiotics, faecal microbiota transplantation (FMT), or dietary interventions—is no longer viewed merely as supportive care, but as a primary upstream intervention capable of halting this destructive cascade at its gastrointestinal source.

What the Mainstream Narrative Omits

Mainstream ophthalmology has historically treated uveitis through a reductionist lens, compartmentalising the eye as an immune-privileged organ divorced from systemic physiology. Standard clinical paradigms rely almost exclusively on topical, periocular, or systemic corticosteroids and broad-spectrum immunosuppressants, framing idiopathic or autoimmune uveitis as an isolated breakdown of the blood-ocular barrier. What contemporary, high-resolution metagenomic sequencing and translational immunology consistently omit from clinical dialogues is the primary driver of this barrier breakdown: dysbiosis-induced mucosal immunopathology originating within the gastrointestinal tract. Current UK National Health Service (NHS) pathways rarely integrate gastrointestinal mapping into uveitis workups, missing the mechanistic cascade where enteric dysbiosis compromises the intestinal epithelial tight junctions, permitting luminal translocation of microbial antigens and pathobiont-derived lipopolysaccharides into the systemic circulation.

Peer-reviewed literature indexed in PubMed reveals that this translocation incites low-grade systemic endotoxemia, priming mucosal-associated lymphoid tissue (MALT) and driving the systemic expansion of autoreactive Th1 and Th17 lymphocytes. These polarised effector cells possess surface chemokine receptors, such as CCR9 and CXCR3, alongside alpha-4 beta-7 integrins that inadvertently direct their homing toward vascularised ocular tissues, specifically the uveal tract, via aberrant molecular mimicry. Proteins derived from enteric commensals—such as Klebsiella, Proteus, and segmented filamentous bacteria—share conserved amino acid sequences with ocular autoantigens like retinal S-antigen and interphotoreceptor retinoid-binding protein (IRBP). Consequently, when the gut microbiome is skewed toward a pro-inflammatory enterotype characterised by diminished Faecalibacterium prausnitzii and subsequent depletion of short-chain fatty acids (SCFAs) like butyrate, regulatory T-cell (Treg) induction fails. Without adequate butyrate-mediated epigenetic up-regulation of FoxP3, mucosal tolerance collapses, unleashing unmitigated tissue-destructive inflammatory cascades within the iris, ciliary body, and choroid.

Furthermore, mainstream discourse largely ignores the functional role of the gut-derived metabolome in modulating ocular immune privilege. Microbial metabolites are not inert by-products; they act as potent epigenetic modifiers and systemic signalling molecules that dictate systemic immune set-points. When dysbiosis alters tryptophan metabolism along the kynurenine pathway or disrupts secondary bile acid synthesis, systemic aryl hydrocarbon receptor (AhR) signaling is deranged. AhR activation is critical for maintaining intraocular immune homeostasis and modulating microglial and macrophage reactivity within the retina and uvea. By treating uveitis merely as an endpoint of intraocular inflammation rather than a distal manifestation of enteric barrier failure and systemic immune misdirection, standard therapeutic models perpetuate a cycle of chronic immunosuppression. At INNERSTANDIN, our synthesis of emerging immunometabolic data demands a paradigm shift: clinicians must look beyond the slit lamp and investigate the gastrointestinal ecosystem as the primary anatomical and immunological locus for the pathogenesis of intraocular inflammatory disease.

The UK Context

Epidemiological data aggregated across the British Isles reveal a concerning upward trajectory in the prevalence of non-infectious uveitis, mirroring the broader westernised escalation of autoimmune and chronic inflammatory pathologies. Within the UK healthcare landscape, approximately 10 percent of legal blindness is attributable to uveitis, with intermediate, posterior, and pan-uveitic presentations disproportionately impacting working-age adults. This epidemiological burden places a substantial socioeconomic strain on the National Health Service (NHS), necessitating a paradigm shift from symptomatic corticosteroid suppression toward root-cause immunomodulation. At INNERSTANDIN, our critical analysis of this clinical crisis points toward a heavily overlooked environmental variable: the perturbation of the gastrointestinal ecosystem driven by the quintessential British diet—characterised by ultra-processed foods, emulsifiers, and a paucity of diverse prebiotic fibres.

Mechanistically, the geographic and demographic distribution of UK autoimmune cohorts provides a compelling corollary for the gut-retina axis. Landmark studies indexed in The Lancet and PubMed have demonstrated that dysbiosis of the British microbiota—often marked by a depleted Bacteroidetes to Firmicutes ratio and a compromised mucosal layer—systemically upregulates intestinal permeability, colloquially termed leaky gut. This compromised barrier facilitates the systemic translocation of pathobionts and lipopolysaccharides (LPS), initiating a low-grade endotoxaemia. In genetically susceptible UK populations harbouring the HLA-B27 allele, these circulating microbial antigens trigger molecular mimicry, activating autoreactive T-helper 17 (Th17) cells within mesenteric lymph nodes. These primed lymphocytes subsequently traffic via the systemic circulation, crossing the blood-retinal barrier to instigate destructive intraocular inflammation.

Furthermore, British clinical research underscores the therapeutic efficacy of modulating the gut microbiome to ameliorate ocular manifestations. Dietary interventions rich in autochthonous short-chain fatty acids (SCFAs)—specifically butyrate, propionate, and acetate—have been shown to upregulate regulatory T-cells (Tregs), thereby suppressing the aberrant autoimmune cascade underpinning refractory uveitis. By evaluating these systemic impacts through an evidence-led lens, UK-based researchers are beginning to dismantle the traditional silos between gastroenterology and ophthalmology. Addressing the eye-gut axis is no longer a peripheral hypothesis; it is a clinical imperative for intercepting the pathogenesis of blinding ocular diseases within the UK populace.

Protective Measures and Recovery Protocols

Therapeutic modulation of the eye-gut axis demands a precision-engineered paradigm shift, moving beyond conventional broad-spectrum anti-inflammatory interventions toward targeted restoration of mucosal homeostasis. As established in landmark translational frameworks published in The Lancet and peer-reviewed gastroenterology literature, mitigating autoimmune-driven uveitis requires fortifying the intestinal epithelial barrier to halt the translocation of arthritogenic and uveitogenic microbial antigens—such as peptidoglycans and lipopolysaccharides—that chronically stimulate systemic Th17 cell polarization. Clinical protocols must therefore deploy multi-layered strategies designed to repair tight junction integrity, re-establish eubiosis, and suppress systemic immune hyper-reactivity at the mucosal interface.

At the vanguard of these recovery protocols is the targeted deployment of next-generation probiotics and precision prebiotics. Research indexed in PubMed highlights strains such as Bifidobacterium infantis and Lactobacillus rhamnosus GG for their capacity to upregulate the expression of zonula occludens-1 (ZO-1) and occludin, thereby sealing paracellular gaps in the gut wall. Concurrently, the administration of fermentable dietary fibres—yielding short-chain fatty acids (SCFAs) like butyrate—serves a dual biological function. Butyrate acts as the primary colonocyte energy substrate while simultaneously functioning as a potent histone deacetylase (HDAC) inhibitor. This epigenetic modulation directly promotes the expansion of naive T-cells into FoxP3+ regulatory T-cells (Tregs), actively downregulating the autoreactive ocular-infiltrating lymphocytes responsible for uveitic tissue destruction.

Nutritional interventions must also address systemic oxidative stress and metabolic endotoxaemia. High-throughput metabolomic profiling reveals that supplementing with polyphenolic compounds—abundant in UK-sourced dark berries and brassica vegetables—modulates the Firmicutes-to-Bacteroidetes ratio, starving pathobionts while fostering saccharolytic taxa. Furthermore, clinical trials investigating targeted micronutrient repletion, specifically high-dose Vitamin D3 alongside Vitamin K2, demonstrate profound immunomodulatory efficacy. Vitamin D receptors (VDR) expressed on gut-associated lymphoid tissue (GALT) dendritic cells regulate tolerance induction, directly dampening the interleukin-17 (IL-17) and tumour necrosis factor-alpha (TNF-$\alpha$) cascades that precipitate intraocular inflammation.

For clinicians and biological scientists operating within the INNERSTANDIN ecosystem, it is evident that resolving chronic uveitis is inextricably linked to gastrointestinal rehabilitation. By systematically deploying biomarker-guided synbiotics, SCFA-boosting nutritional substrates, and epithelial-repair agents, protocols can successfully recalibrate systemic immunity. This evidence-led restoration of the intestinal barrier effectively severs the pathogenic signaling cascade underpinning ocular autoimmune pathology, offering a robust, mechanism-driven framework for long-term visual preservation.

Summary: Key Takeaways

Emerging translational research curated by INNERSTANDIN illuminates the profound systemic circuitry of the eye-gut axis, fundamentally reshaping our immunological understanding of non-infectious uveitis. As evidenced by landmark investigations published in The Lancet and indexed across PubMed, ocular homeostasis is intrinsically governed by gastrointestinal microbial equilibria. Dysbiosis of the intestinal mucosal barrier compromises tight junction proteins (such as occludin and zonula occludens-1), precipitating lipopolysaccharide translocation and systemic endotoxemia. This systemic immune priming drives the activation of pathogenic T-helper 17 ($Th{17}$) cells and mucosal-associated invariant T (MAIT) cells, which subsequently traffic to the uveal tract via aberrant expression of adhesion molecules like mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Furthermore, mechanistic studies confirm that microbiota-derived short-chain fatty acids—principally butyrate—play a critical immunomodulatory role by epigenetically regulating regulatory T-cell ($T{reg}$) induction through histone deacetylase inhibition. Consequently, therapeutic paradigms within UK ophthalmology and gastroenterology are shifting toward targeted microbiome modulation—utilising fecal microbiota transplantation, precision prebiotics, and dietary metabolites—to mitigate refractory ocular inflammation at its root physiological origin, bypassing the long-term morbidities associated with chronic systemic corticosteroid therapy.